BC
VRTX icon

Belmont Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Belmont Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-15
Closed -$5.28K – 198
2023
Q2 		$5.28K Sell
15
-5
-25% -$1.69K ﹤0.01% 160
2023
Q1 		$6.3K Hold
20
– – 0.01% 114
2022
Q4 		$6K Hold
20
– – 0.01% 117
2022
Q3 		$6K Buy
+20
New +$5.75K 0.01% 108

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Belmont Capital's VRTX Position: Q3 2023 in Review

Belmont Capital sold out of Vertex Pharmaceuticals (VRTX) in Q3 2023, closing a stake of 15 shares — an estimated $5.28K sold.

Belmont Capital first reported a position in VRTX in Q3 2022 and held it in 4 quarters. The position peaked at $6.3K in Q1 2023. 1,277 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

  • Belmont Capital reported no remaining Vertex Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Belmont Capital sold 15 Vertex Pharmaceuticals shares in Q3 2023, an estimated $5.28K.
  • Belmont Capital first reported a position in Vertex Pharmaceuticals in Q3 2022 and held it in 4 quarters.
  • Belmont Capital's Vertex Pharmaceuticals position peaked at $6.3K in Q1 2023.
  • 1,277 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on Belmont Capital's 13F filing for Q3 2023, filed 13 Nov 2023.